Likewise, the Hsp90 inhibitors being used for asthma, IPF or PAH may also block heme-maturation of sGC, creating pathologic heme-free sGC, and consequently reduce sGC activation in these diseased conditions. Here, HSP90AB1 is linked to idiopathic pulmonary fibrosis.